Switch from antagonist to agonist after addition of a DOTA chelator to a somatostatin analog.
OBJECTIVE
Peptide receptor targeting has become an increasingly attractive method to target tumors diagnostically and radiotherapeutically. Peptides linked to a variety of chelators have been developed for this purpose. They have, however, rarely been tested for their agonistic or antagonistic properties. We report here on a somatostatin antagonist that switched to an agonist upon coupling to a DOTA chelator.


METHODS
Two novel somatostatin analogs, 406-040-15 and its DOTA-coupled counterpart 406-051-20, with and without cold Indium labeling, were tested for their somatostatin receptor subtypes 1-5 (sst(1)-sst(5)) binding affinity using receptor autoradiography. Moreover, they were tested functionally for their ability to affect sst(2) and sst(3) internalization in vitro in HEK293 cells stably expressing the human sst(2) or sst(3) receptor, using an immunofluorescence microscopy-based internalization assay.


RESULTS
All three compounds were characterized as pan-somatostatin analogs having a high affinity for all five sst. In the sst(2) internalization assay, all three compounds showed an identical behavior, namely, a weak agonistic effect complemented by a weak antagonistic effect, compatible with the behavior of a partial agonist. Conversely, in the sst(3) internalization assay, 406-040-15 was a full antagonist whereas its DOTA-coupled counterpart, 406-051-20, with and without Indium labeling, switched to a full agonist.


CONCLUSIONS
Adding the DOTA chelator to the somatostatin analog 406-040-15 triggers a switch at sst(3) receptor from an antagonist to an agonist. This indicates that potential radioligands for tumor targeting should always be tested functionally before further development, in particular if a chelator is added.
Reubi
Jean Claude
JC
Division of Cell Biology and Experimental Cancer Research, Institute of Pathology, University of Berne, PO Box 62, Murtenstrasse 31, 3010 Berne, Switzerland. reubi@pathology.unibe.ch
Erchegyi
Judit
J
Cescato
Renzo
R
Waser
Beatrice
B
Rivier
Jean E
JE
D002460:Cell Line; D002614:Chelating Agents / Q000737:chemistry*; D006573:Heterocyclic Compounds, 1-Ring / Q000737:chemistry*; D006801:Humans; D021381:Protein Transport / Q000187:drug effects; D017481:Receptors, Somatostatin / Q000819:agonists* / Q000037:antagonists & inhibitors* / Q000378:metabolism; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology*
D002614:Chelating Agents; D006573:Heterocyclic Compounds, 1-Ring; D017481:Receptors, Somatostatin; C106140:somatostatin receptor sst2A; C071349:1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acid; D013004:Somatostatin
Cancer Res. 1990 Sep 15;50(18):5969-77
2168286
Eur J Nucl Med. 2000 Mar;27(3):273-82
10774879
J Nucl Med. 2009 Jun;50(6):936-41
19443580
Eur J Nucl Med Mol Imaging. 2003 Oct;30(10):1338-47
12937948
Nucl Med Commun. 2002 May;23(5):493-9
11973491
Nat Rev Endocrinol. 2009 Jul;5(7):382-93
19488074
Clin Cancer Res. 2009 Aug 15;15(16):5240-9
19671861
Mol Pharmacol. 2005 Jul;68(1):90-101
15855408
J Nucl Med. 2008 Feb;49(2):318-26
18199616
J Med Chem. 2008 Jul 10;51(13):4030-7
18543899
J Neurochem. 2004 Jun;89(5):1057-91
15147500
Bioconjug Chem. 2008 Jan;19(1):192-200
18020401
Proc Natl Acad Sci U S A. 2006 Oct 31;103(44):16436-41
17056720
J Med Chem. 2009 May 14;52(9):2733-46
19351180
Clin Cancer Res. 2008 Apr 1;14(7):2019-27
18381940
Endocr Rev. 2003 Aug;24(4):389-427
12920149
J Nucl Med. 1999 Jun;40(6):1029-44
10452322
Eur J Nucl Med Mol Imaging. 2002 May;29(5):597-606
11976797
Mol Pharmacol. 1996 Oct;50(4):709-15
8863814
Eur J Nucl Med Mol Imaging. 2003 Feb;30(2):247-58
12552343
J Nucl Med. 2006 Mar;47(3):502-11
16513620
Endocrinology. 2004 Jun;145(6):2876-85
15016723
J Pharmacol Exp Ther. 2004 Sep;310(3):865-70
15113845
Semin Nucl Med. 2006 Jul;36(3):228-47
16762613
J Nucl Med. 2008 Nov;49(11):1735-8
18927341
Eur J Nucl Med Mol Imaging. 2007 Aug;34(8):1198-208
17262215